Suppr超能文献

用于降低绝经前妇女乳腺 X 线摄影密度的化学预防剂:临床试验的系统评价。

Chemoprevention Agents to Reduce Mammographic Breast Density in Premenopausal Women: A Systematic Review of Clinical Trials.

机构信息

Department of Surgery, Division of Public Health Sciences, Washington University School of Medicine, St Louis, MO, USA.

Bernard Becker Medical Library, Washington University School of Medicine, St Louis, MO, USA.

出版信息

JNCI Cancer Spectr. 2021 Jan 22;5(1). doi: 10.1093/jncics/pkaa125. eCollection 2021 Feb.

Abstract

BACKGROUND

Higher mammographic breast density (MBD) is associated with an increased risk of breast cancer when compared with lower MBD, especially in premenopausal women. However, little is known about the effectiveness of chemoprevention agents in reducing MBD in premenopausal women without a history of breast cancer. Findings from this review should provide insight on how to target MBD in breast cancer prevention in premenopausal women with dense breasts.

METHODS

We searched 9 electronic databases for clinical trials in English, Spanish, French, or German published until January 2020. Articles evaluating the association of pharmacological agents and MBD were included. Data were extracted on methods, type and dose of intervention, outcomes, side effects, and follow up. Quality of the studies was assessed using the US Preventive Services Task Force criteria.

RESULTS

We identified 7 clinical trials evaluating the associations of 6 chemoprevention agents with changes in MBD in premenopausal women without history of breast cancer. The studies evaluated selective estrogen-receptor modulators (n = 1); gonadotropin-releasing hormone agonists (n = 2); isoflavones (n = 1); vitamin D (n = 1); and Boswellia, betaine, and mayo-inositol compound (n = 1). Hormonal interventions were associated with net reductions in percent density (tamoxifen [13.4%], leuprolide acetate [8.9%], and goserelin [2.7%]), whereas nonhormonal (vitamin D and isoflavone) interventions were not. However, MBD returned to preintervention baseline levels after cessation of gonadotropin-releasing hormone agonists.

CONCLUSIONS

A limited number of chemoprevention agents have been shown to reduce MBD in premenopausal women. Identification of new and well-tolerated chemoprevention agents targeting MBD and larger studies to confirm agents that have been studied in small trials are urgent priorities for primary breast cancer prevention in premenopausal women with dense breasts.

摘要

背景

与低乳腺密度(MBD)相比,较高的乳腺密度(MBD)与乳腺癌风险增加相关,尤其是在绝经前妇女中。然而,对于没有乳腺癌病史的绝经前妇女,化学预防剂在降低 MBD 方面的有效性知之甚少。本综述的结果应能深入了解如何针对致密乳房的绝经前妇女的 MBD 进行乳腺癌预防。

方法

我们在英语、西班牙语、法语或德语的 9 个电子数据库中搜索了截至 2020 年 1 月发表的临床试验。纳入评估药物与 MBD 相关性的文章。提取方法、干预类型和剂量、结果、副作用和随访的数据。使用美国预防服务工作组标准评估研究质量。

结果

我们确定了 7 项临床试验,评估了 6 种化学预防剂在无乳腺癌病史的绝经前妇女中与 MBD 变化的相关性。这些研究评估了选择性雌激素受体调节剂(n=1);促性腺激素释放激素激动剂(n=2);异黄酮(n=1);维生素 D(n=1);以及 Boswellia、甜菜碱和肌醇复合剂(n=1)。激素干预与密度百分比的净减少相关(他莫昔芬[13.4%]、亮丙瑞林醋酸盐[8.9%]和戈舍瑞林[2.7%]),而非激素(维生素 D 和异黄酮)干预则没有。然而,在停止使用促性腺激素释放激素激动剂后,MBD 恢复到干预前的基线水平。

结论

少数化学预防剂已被证明可降低绝经前妇女的 MBD。确定新的和耐受性良好的针对 MBD 的化学预防剂,并对已在小型试验中研究的药物进行更大规模的研究,是致密乳房的绝经前妇女进行原发性乳腺癌预防的当务之急。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2bea/7853173/ce0a921817a5/pkaa125f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验